"A full analysis will take some time but
encouragingly, available data suggests that Bronchitol performs better in some patients with high
disease burden."
“A presentation of the findings of the B305 study will be made at an international scientific
respiratory conference where I expect it will attract significant attention.
It attracted significant attention yesterday.
Clutching at straws, or is there something left in the tank? Am I wrong in thinking that with net tangibles at 25c a share they might be better off winding the show up before wasting anymore money.
Im only holding a small parcel that I bought yesterday more out of curiosity than anything else. Couldnt be further removed, but I feel for the tremendous devastation of wealth suffered by existing shareholders.
ph 3 trial fails primary endpoint, page-28
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.3¢ |
Change
-0.001(2.27%) |
Mkt cap ! $59.04M | |||
| Open | High | Low | Value | Volume |
| 4.4¢ | 4.4¢ | 4.2¢ | $39.11K | 895.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 752779 | 4.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.4¢ | 200000 | 1 |
View Market Depth
| Last trade - 15.58pm 04/10/2024 (20 minute delay) ? |
| SNT (ASX) Chart |